AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30522992
Drug: Usual psychopharmacological
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual psychopharmacological therapy
Trial: 30523039
Drug: Various modifiable
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various modifiable risk factors (e.g., diet, supplement use, physical activity)
Trial: 30523039
Drug: Biomarkers (e.g.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarkers (e.g., metabolomic, transcriptomic, metagenomic, genetic, epigenetic, proteomic markers)
Trial: 30523489
Drug: Blood drug
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood drug concentrations in plasma
Trial: 30524509
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (varenicline + nicotine patch + nicotine lozenge)
Trial: 30525116
Drug: LEV 1,000-3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 1,000-3,000 mg/day
Trial: 30525443
Drug: Free drug
RxNorm normalized name: sumatriptan 6 MG per 0.5 ML Needle-Free Drug Delivery System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free drug (irinotecan)
Trial: 30526213
Drug: Cytisine, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytisine, a partial agonist for the α4β2 nicotinic acetylcholine receptor, administered in ascending single doses.
Trial: 30526535
Drug: Initial high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial high-dose ganciclovir (6 mg)
Trial: 30526535
Drug: Maintenance dose
RxNorm normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance dose of ganciclovir (not specified)
Trial: 30527329
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg tablets
Trial: 30527329
Drug: Raltegravir chewable
RxNorm normalized name: raltegravir Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir chewable tablets
Trial: 30527329
Drug: Raltegravir oral
RxNorm normalized name: raltegravir Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir oral granules
Trial: 30527329
Drug: Raltegravir (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (all formulations)
Trial: 30527774
Drug: Low-Molecular-Weight Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Molecular-Weight Heparin
Trial: 30528561
Drug: tazobactam/ceftolozane 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tazobactam/ceftolozane 1.5 g (tazobactam 0.5 g/ceftolozane 1 g) plus metronidazole 500 mg intravenously every 8 h for 60 min for 4-14 days
Trial: 30528623
Drug: us-TnI <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: us-TnI < 1 ng/L directly on admission
Trial: 30528623
Drug: us-TnI <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: us-TnI < 2 ng/L and 0/1h delta < 1 ng/L
Trial: 30528623
Drug: us-TnI ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: us-TnI ≥ 25 ng/L on admission or 0/1h delta ≥ 6 ng/L
Trial: 30529029
Drug: Lopinavir-ritonavir super-boosting
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir super-boosting with additional ritonavir (one-to-one ratio) during rifampicin treatment
Trial: 30529085
Drug: Levonorgestrel IUD
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel IUD (52-mg, 20 mcg/d initial release)
Trial: 30530477
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (no pessary)
Trial: 30530721
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral therapy with tenofovir disoproxil fumarate/emtricitabine
Trial: 30530985
Drug: Oral d3-l-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral d3-l-carnitine
Trial: 30530985
Drug: Chronic l-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic l-carnitine supplementation
Trial: 30531015
Drug: Intrathecal injection
RxNorm normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal injection of Wharton's jelly-derived mesenchymal stem cells (average dose of 0.42 × 10^6 cells)
Trial: 30531565
Drug: Levonorgestrel 52-mg
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel 52-mg intrauterine system (IUS)
Trial: 30534007
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg or 20 mg, bodyweight-adjusted, single-dose)
Trial: 30534008
Drug: Rivaroxaban (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (tablet and oral suspension)
Trial: 30534187
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil omega-3 (3.17 g per day; eicosapentaenoic acid 2.15 g; docosahexaenoic acid 1.02 g)
Trial: 30534374
Drug: Rasagiline 1
RxNorm normalized name: rasagiline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 1 mg once daily
Trial: 30535053
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care models that integrate comorbidities, mainly via transdiagnostic self-management support, interprofessional collaboration, and digital approaches for treatment, monitoring, and communication.
Trial: 30535190
Drug: Ceftaroline 600
RxNorm normalized name: ceftaroline 600 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftaroline 600 mg as a 1 h intravenous infusion
Trial: 30536725
Drug: G-AgP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-AgP
Trial: 30537529
Drug: Sirolimus (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (loading dose of 1.8 mg/m)
Trial: 30537545
Drug: 2000 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 μg vitamin D oral bolus
Trial: 30537877
Drug: Interactions with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactions with biological and nonbiological network members regarding risk information and management strategies.
Trial: 30537968
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide (CP) gel for 1 hour daily for 3 weeks
Trial: 30537968
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide (CP) gel
Trial: 30538057
Drug: Aspirin/rivaroxaban co-therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin/rivaroxaban co-therapy
Trial: 30538817
Drug: Anifrolumab treatment
RxNorm normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anifrolumab treatment
Trial: 30539492
Drug: Locoregional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional treatment (LRT) including radiotherapy, surgery, or both
Trial: 30540645
Drug: ST-2 levels
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ST-2 levels greater than 54 ng/ml
Trial: 30540645
Drug: BNP levels
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP levels greater than 567 pg/ml
Trial: 30541333
Drug: LifeCourse (LC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LifeCourse (LC) program delivered by community health workers (CHWs) with standardized monthly 1-hour home visits based on palliative care guidelines and motivational interviewing.
Trial: 30541505
Drug: Point-of-care testing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point-of-care testing for procalcitonin (PCT) using 0.5 ml of whole blood; results available within 20 minutes.
Trial: 30542286
Drug: Low-dose azacitidine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose azacitidine (AZA) in combination with PPARγ agonist pioglitazone (PGZ)
Trial: 30542289
Drug: Daily undulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily undulating periodization (DUP) resistance training
Trial: 30542377
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of everolimus, lapatinib, and capecitabine
Trial: 30542622
Drug: Dalteparin sodium
RxNorm normalized name: Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin sodium (initial dose of 5000 IU, adjustable by 500 or 1000 IU increments)
Trial: 30543050
Drug: Gastrin-releasing peptide
RxNorm normalized name: Gastrin-releasing peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrin-releasing peptide receptor antagonist
Trial: 30543347
Drug: Alpelisib 400
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpelisib 400 mg once daily plus fulvestrant 500 mg
Trial: 30543347
Drug: Alpelisib 300
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib 300 to 400 mg once daily plus fulvestrant
Trial: 30543347
Drug: Alpelisib 300
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib 300 mg once daily plus fulvestrant
Trial: 30544060
Drug: Upfront DPYD-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront DPYD-guided dose individualisation with initial dose reduction of 25% or 50% based on DPYD variants screening.
Trial: 30544060
Drug: Upfront DPYD-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront DPYD-guided dose individualisation.
Trial: 30546962
Drug: Zolbetuximab in
RxNorm normalized name: zolbetuximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolbetuximab in conjunction with chemotherapy
Trial: 30548438
Drug: AVXS-101 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AVXS-101 gene replacement therapy
Trial: 30551202
Drug: Carbonic anhydrase
RxNorm normalized name: Carbonic anhydrase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbonic anhydrase inhibitor (CAI) treatment
Trial: 30551202
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (natural history)
Trial: 30552056
Drug: Ledipasvir (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) in a single combination tablet once daily for 12 weeks
Trial: 30552156
Drug: Vinflunine 280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinflunine 280 mg/m2
Trial: 30552156
Drug: Vinflunine 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinflunine 320 mg/m2
Trial: 30554141
Drug: GDF-15 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDF-15 levels <564 pg/L
Trial: 30555051
Drug: Coformulated elvitegravir
RxNorm normalized name: Elvitegravir
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Coformulated elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once daily, taken after haemodialysis for up to 96 weeks.
Trial: 30555048
Drug: Sofosbuvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (400 mg) and Velpatasvir (100 mg) tablet once daily for 12 weeks
Trial: 30555280
Drug: Repetitive administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repetitive administration of intravenous levosimendan after discharge from an acute episode of worsening heart failure.
Trial: 30555280
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for advanced heart failure.
Trial: 30555384
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy modules
Trial: 30555714
Drug: Lumbar Spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar Spinal Manipulative Therapy (SMT)
Trial: 30556332
Drug: Testosterone (T)/Nestorone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (T)/Nestorone (NES) combination gel applied by men (62 mg/8 mg)
Trial: 30557521
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg every 2 weeks for 2 years or until confirmed disease progression or unacceptable toxicity
Trial: 30557741
Drug: Wireless Motility
RxNorm normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless Motility Capsule (WMC)
Trial: 30558613
Drug: Eating breakfast
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eating breakfast daily throughout childhood
Trial: 30558613
Drug: Daily family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily family dinner
Trial: 30558909
Drug: Asfotase alfa
RxNorm normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asfotase alfa (1 mg/kg three times per week subcutaneously, adjusted to 3 mg/kg three times per week if required) for up to 7 years
Trial: 30558987
Drug: Umbralisib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbralisib (800 mg once daily) plus Ibrutinib (420 mg for CLL, 560 mg for MCL)
Trial: 30559420
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of an antisense oligonucleotide to restore correct splicing
Trial: 30559424
Drug: AZD5991 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5991 in combination with bortezomib or venetoclax
Trial: 30559603
Drug: PRO-SELF© Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO-SELF© Plus Pain Control Program (PCP), 6-week intervention, weekly psychoeducational sessions
Trial: 30559966
Drug: Physical Exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Exercise and Dietary Therapy (PED-t)
Trial: 30562390
Drug: Preconception anemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preconception anemia (hemoglobin <12 g/dL)
Trial: 30562587
Drug: CMVPepVax (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMVPepVax (two injections at days 28 and 56 post-HCT)
Trial: 30563754
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDCT) and autologous stem-cell transplantation (ASCT)
Trial: 30563875
Drug: Midostaurin added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin added to chemotherapy
Trial: 30563875
Drug: Midostaurin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin as single-agent maintenance therapy
Trial: 30564373
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy eligibility
Trial: 30565371
Drug: COMBO stent
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMBO stent treatment
Trial: 30567529
Drug: Maintenance MAGE-A3
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maintenance MAGE-A3 CI monotherapy
Trial: 30569038
Drug: Novel nano-iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel nano-iron supplement
Trial: 30569759
Drug: Fluocinolone intravitreal
RxNorm normalized name: Fluocinolone Acetonide Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocinolone intravitreal implant (ILUVIEN)
Trial: 30570077
Drug: Instituto Butantan
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Instituto Butantan seasonal trivalent influenza vaccine (TIV)
Trial: 30570358
Drug: Subcutaneous Echogenicity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Echogenicity Grade
Trial: 30570358
Drug: Subcutaneous Echo-Free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Echo-Free Space Grade
Trial: 30570502
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for POP
Trial: 30570649
Drug: Pembrolizumab, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab, 200 mg administered intravenously every 3 weeks until disease progression, unacceptable toxic effects, or study withdrawal, for up to 2 years.
Trial: 30570649
Drug: Pembrolizumab treatment-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab treatment-related adverse events.
Trial: 30570744
Drug: Mocetinostat (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mocetinostat (70 mg 3 times per week escalating to 90 mg TIW)
Trial: 30570763
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) pertuzumab (600 mg maintenance dose)
Trial: 30570763
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) pertuzumab (1200 mg loading dose)
Trial: 30570763
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) pertuzumab and trastuzumab (fixed-dose combination)
Trial: 30571194
Drug: Contemporary Cohort
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contemporary Cohort (CC)
Trial: 30571969
Drug: Caspase 1/11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspase 1/11 invalidation or pharmacological inhibition by Ac-YVAD-CMK injection
Trial: 30572891
Drug: Smartphone app-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone app-based medication reporting
Trial: 30572920
Drug: Aedes aegypti
RxNorm normalized name: Aedes taeniorhynchus
DrugBank: Aedes taeniorhynchus (DB10691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aedes aegypti salivary gland homogenate antibody intensity determinations by ELISA assays
Trial: 30572922
Drug: LCAR-B38M CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCAR-B38M CAR T cell therapy
Trial: 30573448
Drug: Tapering of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering of interventions (for responders)
Trial: 30573492
Drug: Psychotropic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medication treatment
Trial: 30573492
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of psychotropic medication treatment
Trial: 30573564
Drug: Single-agent bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-agent bortezomib
Trial: 30574672
Drug: Risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 150 mg subcutaneously once every 4 weeks for 12 weeks
Trial: 30576085
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide (TAF) 25 mg daily
Trial: 30576221
Drug: Nasal High-Flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal High-Flow Therapy
Trial: 30576970
Drug: Durvalumab 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 10 mg/kg intravenously every 2 weeks for up to 12 months
Trial: 30577927
Drug: Psychotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy treatment for depression (PCIT-ED)
Trial: 30577988
Drug: Buparlisib plus
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib plus weekly paclitaxel
Trial: 30577988
Drug: Systemic chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy, paclitaxel (70 mg/m2)
Trial: 30578023
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg once daily, taken orally without food, until progression or intolerance.
Trial: 30579045
Drug: Open-label antidepressant
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label antidepressant treatment for up to 24 months
Trial: 30579270
Drug: Convection-enhanced delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convection-enhanced delivery (CED) using 124I-8H9, a radioimmunotherapeutic agent, with a mean infusate volume of 3.84-4.54 ml.